WASHINGTON, DC, Oct. 3 – Pluvita, a drug-discovery and development company, has acquired a majority stake in Diogenics, a privately held genomic firm, the companies said on Wednesday.

The acquisition, for an undisclosed amount, was designed to allow Pluvita to combine its bioinformatics, information management, and clinical databases with Diogenics’ wet-lab capabilities, model systems, and intellectual property assets, Pluvita said in a statement.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.